BR112017007311A2 - espiro-indols para o tratamento e profilaxia da infecção respiratória do vírus sincicial (rsv) - Google Patents

espiro-indols para o tratamento e profilaxia da infecção respiratória do vírus sincicial (rsv)

Info

Publication number
BR112017007311A2
BR112017007311A2 BR112017007311A BR112017007311A BR112017007311A2 BR 112017007311 A2 BR112017007311 A2 BR 112017007311A2 BR 112017007311 A BR112017007311 A BR 112017007311A BR 112017007311 A BR112017007311 A BR 112017007311A BR 112017007311 A2 BR112017007311 A2 BR 112017007311A2
Authority
BR
Brazil
Prior art keywords
rsv
infection
indols
spiro
prophylaxis
Prior art date
Application number
BR112017007311A
Other languages
English (en)
Other versions
BR112017007311B1 (pt
Inventor
Lunn Graham
Miguel Gascon Simorte Jose
Paradowski Michael
Mathews Neil
Ward Simon
Cockerill Stuart
Original Assignee
Reviral Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51946966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017007311(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reviral Ltd filed Critical Reviral Ltd
Publication of BR112017007311A2 publication Critical patent/BR112017007311A2/pt
Publication of BR112017007311B1 publication Critical patent/BR112017007311B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Abstract

benzimidazóis de fórmula (i): fórmula (i) em que: - um de x e y é um átomo de n ou um átomo de c substituído, e o outro é ch; - l é uma ligação simples, alquileno c1-3, alquenileno c2-3 ou alquinileno c2-3; - r1 é alquil c1-6, alquenil c2-6, alquinil c2-6, cicloalquil de 3 a 10 membros, heterociclil de 5 a 10 membros ou heteroaril de 5 a 12 membros, cada um dos quais é não substituído ou substituído; - z é haolgênio, haloalquil c1-6, nitro, -cn, -n(r2)2, -or2, -sr2, -s(=o)r2, ou -s (=o)2r2; - cada r2 representa independentemente hidrogênio, alquil c1-6, alquenil c2-6 ou alquinil c2-6, em que os referidos grupos alquil, alquenil e alquinil são grupos não substituídos ou substituídos; e - m é 0 ou 1; ou um sal farmaceuticamente aceitável do mesmo que são inibidores de rsv e podem portanto ser usados para tratar ou prevenir uma infecção por rsv.
BR112017007311-0A 2014-10-07 2015-10-06 Espiro-indols para o tratamento e profilaxia da infecção respiratória do vírus sincicial (rsv) BR112017007311B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417707.5A GB201417707D0 (en) 2014-10-07 2014-10-07 Pharmaceutical compounds
GB1417707.5 2014-10-07
PCT/GB2015/052920 WO2016055780A1 (en) 2014-10-07 2015-10-06 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)

Publications (2)

Publication Number Publication Date
BR112017007311A2 true BR112017007311A2 (pt) 2017-12-19
BR112017007311B1 BR112017007311B1 (pt) 2022-11-22

Family

ID=51946966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007311-0A BR112017007311B1 (pt) 2014-10-07 2015-10-06 Espiro-indols para o tratamento e profilaxia da infecção respiratória do vírus sincicial (rsv)

Country Status (30)

Country Link
US (1) US10106539B2 (pt)
EP (1) EP3204375B1 (pt)
JP (1) JP6695334B2 (pt)
KR (2) KR102561796B1 (pt)
CN (1) CN107108557B (pt)
AR (1) AR102181A1 (pt)
AU (1) AU2015329778B2 (pt)
BR (1) BR112017007311B1 (pt)
CA (1) CA2963740C (pt)
CL (1) CL2017000839A1 (pt)
CO (1) CO2017004603A2 (pt)
CY (1) CY1121564T1 (pt)
DK (1) DK3204375T3 (pt)
ES (1) ES2718976T3 (pt)
GB (1) GB201417707D0 (pt)
HR (1) HRP20190808T1 (pt)
HU (1) HUE043553T2 (pt)
LT (1) LT3204375T (pt)
MX (1) MX2017004425A (pt)
NZ (1) NZ731323A (pt)
PE (1) PE20170949A1 (pt)
PL (1) PL3204375T3 (pt)
PT (1) PT3204375T (pt)
RS (1) RS58706B1 (pt)
RU (1) RU2734248C2 (pt)
SG (1) SG11201702766YA (pt)
SI (1) SI3204375T1 (pt)
TR (1) TR201903362T4 (pt)
TW (1) TWI718107B (pt)
WO (1) WO2016055780A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305790B1 (en) 2015-06-08 2020-08-05 Shangdong Danhong Pharmaceutical Co., Ltd. Method for preparing imidazole derivative and intermediate thereof and crystal form
JP6944514B2 (ja) 2016-08-04 2021-10-06 アールイーヴァイラル リミテッド ピリミジン誘導体および呼吸器合胞体ウイルス感染の治療または予防におけるそれらの使用
GB201711704D0 (en) * 2017-07-20 2017-09-06 Reviral Ltd Pharmaceutical compounds
GB201721812D0 (en) * 2017-12-22 2018-02-07 Reviral Ltd Pharmaceutical compounds
CN116077494A (zh) * 2023-01-11 2023-05-09 黑龙江中医药大学 一种治疗呼吸道合胞病毒的药物组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102863A (en) * 1980-12-16 1982-06-26 Takeda Chem Ind Ltd Spiroindolinone and its preparation
PL194216B1 (pl) * 1998-01-23 2007-05-31 Sankyo Co Pochodne spiropiperydyny, lekarstwo oraz środek zapobiegawczy lub terapeutyczny zawierające jako składnik czynny te pochodne i zastosowanie pochodnych spiropiperydyny
DE60013836T2 (de) * 1999-06-28 2006-01-19 Janssen Pharmaceutica N.V. Replikationsinhibitoren des respiratorischen synzytialvirus
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2004037247A1 (en) * 2002-10-21 2004-05-06 Irm Llc Oxindoles with anti-hiv activity
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
JP4913061B2 (ja) 2004-10-13 2012-04-11 メルク・シャープ・エンド・ドーム・コーポレイション Cgrp受容体拮抗薬
WO2010103306A1 (en) 2009-03-10 2010-09-16 Astrazeneca Uk Limited Benzimidazole derivatives and their use as antivaral agents
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
CN104903313B (zh) 2012-10-16 2017-12-29 爱尔兰詹森科学公司 Rsv抗病毒化合物
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
KR20160007629A (ko) * 2013-05-14 2016-01-20 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
JP2016518421A (ja) * 2013-05-14 2016-06-23 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 呼吸器合胞体ウイルス感染症の処置および予防のためのアザ−オキソ−インドール
KR20160030271A (ko) * 2013-08-12 2016-03-16 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 아자-옥소-인돌
CN105408330A (zh) * 2013-08-12 2016-03-16 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
BR112016002638A2 (pt) * 2013-08-12 2017-08-01 Hoffmann La Roche novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
EP3033333A1 (en) * 2013-08-15 2016-06-22 F. Hoffmann-La Roche AG Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CN105431419A (zh) * 2013-08-15 2016-03-23 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
KR20160030569A (ko) * 2013-08-15 2016-03-18 에프. 호프만-라 로슈 아게 호흡기 세포융합 바이러스 감염의 치료 및 예방을 위한 신규한 아자-옥소-인돌

Also Published As

Publication number Publication date
TR201903362T4 (tr) 2019-04-22
KR102561796B1 (ko) 2023-07-31
CL2017000839A1 (es) 2017-10-13
NZ731323A (en) 2022-09-30
JP2017530992A (ja) 2017-10-19
SG11201702766YA (en) 2017-05-30
RU2017113026A3 (pt) 2019-03-22
PL3204375T3 (pl) 2019-06-28
TW201625583A (zh) 2016-07-16
EP3204375A1 (en) 2017-08-16
ES2718976T3 (es) 2019-07-05
WO2016055780A1 (en) 2016-04-14
AU2015329778A1 (en) 2017-05-04
US10106539B2 (en) 2018-10-23
HUE043553T2 (hu) 2019-09-30
CA2963740A1 (en) 2016-04-14
AR102181A1 (es) 2017-02-08
AU2015329778B2 (en) 2020-04-23
RU2017113026A (ru) 2018-11-13
TWI718107B (zh) 2021-02-11
CN107108557A (zh) 2017-08-29
JP6695334B2 (ja) 2020-05-20
SI3204375T1 (sl) 2019-05-31
MX2017004425A (es) 2017-10-11
RS58706B1 (sr) 2019-06-28
DK3204375T3 (en) 2019-04-01
LT3204375T (lt) 2019-05-10
US20170305908A1 (en) 2017-10-26
CY1121564T1 (el) 2020-05-29
CA2963740C (en) 2022-11-29
AU2015329778A8 (en) 2017-05-18
GB201417707D0 (en) 2014-11-19
PE20170949A1 (es) 2017-07-13
CN107108557B (zh) 2020-11-10
KR20230116097A (ko) 2023-08-03
EP3204375B1 (en) 2019-02-13
PT3204375T (pt) 2019-04-01
KR20170066577A (ko) 2017-06-14
BR112017007311B1 (pt) 2022-11-22
HRP20190808T1 (hr) 2019-08-23
CO2017004603A2 (es) 2017-10-31
RU2734248C2 (ru) 2020-10-13

Similar Documents

Publication Publication Date Title
BR112017007311A2 (pt) espiro-indols para o tratamento e profilaxia da infecção respiratória do vírus sincicial (rsv)
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018015289A2 (pt) compostos de benzopirazol e análogos dos mesmos
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112018005048B8 (pt) uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
CR20150454A (es) Compuestos amida para el tratamiento de vih
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
EA201792116A1 (ru) Ингибитор янус-киназы
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
BR112016024057A2 (pt) inibidores de quinases heterocíclicos
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
BR112017019699A2 (pt) derivados substituídos por 3-indol, composições farmacêuticas e métodos para uso
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
BR112019003519A2 (pt) compostos de sulfonimidoilpurinona 7-substituídos para o tratamento e profilaxia de infecção por vírus
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2015, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: PFIZER INC. (US)